ANVS - Annovis Bio - DD - June 2021
- Current Price (June 13): 91.00 (found at 47)
- O/S 7M
- Float 4.7M
- Cash ~50M
- Market cap: ~$700M
annovisbio.com
Pipeline: annovisbio.com/technologies
Our Pipeline consists of drugs for chronic neurodegeneration - Alzheimer’s disease (AD), its orphan indication Alzheimer’s disease and dementia in Down syndrome (AD-DS) and Parkinson’s disease (PD). Additionally, we have a compound to treat acute neurodegeneration - traumatic brain injury (TBI) and stroke - and a third compound for advanced AD.
We Are Working to REVERSE the Toxic Cascade
Recent updates
- June 8, 2021 - Expansion of ANVS401 applications - irpages2.eqs.com/websites/anno...
- June 1, 2021 - ANNOVIS BIO’S ANVS401 IMPROVES SPEED AND ACCURACY IN ALZHEIMER’S AND IN PARKINSON’S PATIENTS - irpages2.eqs.com/websites/anno...
- May 21, 2021 - ANNOVIS BIO ANNOUNCES POSITIVE PHASE 2 DATA – ANVS401 IMPROVES COGNITION IN ALZHEIMER’S DISEASE - irpages2.eqs.com/websites/anno...
- Phase 2 full data July / August 2021 for ANVS401 -- Alzheimer’s disease (AD) and Parkinson’s disease (PD) - they haven't said a date yet, but I'm guessing it'll be at the AAIC on July 26-30 -- alz.org/aaic/overview.asp (they are a platinum sponsor...)
Heads up
As always, there's two major warnings with any biotech: data could turn out bad (despite expectations otherwise) and offerings are ever looming (since most biotechs have no revenue). I wouldn't be surprised to see an offering in late June/early July if this price stays up here.
My notes
- They recently did an offering of 1M shares @ 50, putting $50M in the coffers
- As you can see from the trades on this board, I ran into this around 47. It. moves. fast. I currently have no position (have bought and sold several times), but I'll be back in by end of June ahead of data release in July
- I really like this one. I can't find any reason to dislike it, even at 90.
Annovis Bio - ANVS
| Total Followers: | 1 |
|
|
|
| Follow | |